Abstract: The present inventors discovered that microfiltration retentates of whey, and products obtained by treating whey using centrifugation and/or ammonium sulfate precipitation, have the activity of inhibiting rotavirus infection.

Abstract: The present inventors discovered that microfiltration retentates of whey, and products obtained by treating whey using centrifugation and/or ammonium sulfate precipitation, have the activity of inhibiting rotavirus infection.

Abstract: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the omega-6 to the omega-3 fatty acids and their amounts are controlled based on one or more factors including age of the subject, sex of the subject, diet of the subject, the body weight of the subject, medical conditions of the subject, and climate of the subject's living area.

Abstract: A skin function-improving composition for oral ingestion, which contains a milk-fat globule membrane. The composition is inexpensive, is highly safe, can be ingested orally, and has an activity of improving the dry condition of the skin so as to moisturize the skin. In particular, the milk-fat globule membrane is obtained from buttermilk or a processed product thereof. In particular, the composition has an activity of reducing transepidermal water loss or an activity of suppressing epidermal thickness. The composition can be ingested in the form of a food or beverage.

Abstract: The invention provides a method for the treatment of acne comprising orally administering to a person suffering from acne an effective amount of a whey protein fraction containing lactoferrin, and preferably containing further specific whey proteins. The lactoferrin is preferably native bovine lactoferrin and the whey protein fraction is administered at a level of between 10 mg and 2 g lactoferrin per patient per day.

Abstract: A method for the production of an immunostimulant milk product, characterized in that bioconversion is carried out on or a milk substrate with the aid of a Bifidobacterium culture by keeping said substrate in contact with said culture in conditions which are unfavorable with respect to the fermentation of Bifidobacterium. The invention also relates to milk foods and products obtained by said method.

Abstract: The present invention relates to a composition comprising colostrum and at least one agent selected from the group of hydrocolloids, wherein said colostrum and at least one agent are bioconjugated. The bioconjugated composition has improved properties compared to colstrum compositions that are not bioconjugated with a hydrocolloid agent. The composition may be used in a variety of settings, for example for topical application for treating skin diseases and skin conditions. The present invention thus also relates to use of the composition and to a method for the preparation of the composition.

Abstract: The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that can be used to maintain or improve thymus health. One embodiment of the present invention is the use of whey or at least one protein fraction thereof for the preparation of a composition to maintain or improve thymus function.

Abstract: A ruminant reduced-cholesterol dairy product is used as a medicament.

Abstract: The invention provides functional food and beverage that produce, through oral intake, a promotive effect on normal epidermal keratinization, and an epidermal differentiation and keratinization promoter for use in such functional food and beverage. The epidermal differentiation and keratinization promoter of the present invention contains, as an active component, fermented milk whey obtained by fermentation of milk with bacteria including lactic acid bacteria, such as Latobacillus helveticus. The functional food and beverage for promoting epidermal keratinization of the present invention contains the epidermal differentiation and keratinization promoter.

Abstract: An enteral nutrient gel that is excellent at maintaining its solid matter (gel) form in the stomach, does not readily disintegrate or dissolve with a change in pH, is stable in its physical properties even during long-term storage, and can be passed through a feeding tube. The enteral nutrient gel contains agar, alginic acid and/or a salt thereof, soybean protein or a hydrolysate thereof, calcium, magnesium, dextrin, and, optionally, an oligosaccharide, a disaccharide and/or a monosaccharide. A solid composition containing 8 to 30 wt % protein, 2 to 25 wt % fats, and 40 to 70 wt % dextrin is used in preparing the enteral nutrient gel.

Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

Abstract: The invention relates to the use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix, for producing a preparation for the treatment of skin diseases, especially dry skin diseases.

Abstract: Use of one or more of conjugated linoleic acid (CLA), high CLA milk fat, or one or more bovine milk lipid compositions to treat or prevent rotavirus infection.

Abstract: A composition of pesticide is a composed of banana oil, pepper powder, urea, and milk powder. Banana oil is composed of ethyl acetate, n-butyl acetate, n-butanol, ketone, benzol, and xylene. Banana oil is diluted with water at a proper ratio. Pepper powder is added to banana oil to provide an excellent effect of pest killing. Urea is diluted with water at a proper ratio. Milk powder is added to urea to provide protection to plant leaves. With such a composition, a practical improvement of being environmentally conservative, toxicant free, and pollution free is realized.

Abstract: Disclosed are agents for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm and for improving a circadian rhythm, as well as functional food containing such an agent, which may prevent or ameliorate various symptoms, such as sleep disorder or prolonged sleep latency. The agent contains whey as the active component.

Abstract: A composition for killing insects in which the main active ingredient is whey permeate.

Abstract: Biodegradable personal care compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable personal care compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.

Abstract: This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.

Abstract: The invention relates to a nutritional composition comprising colostrum and a fat blend that is particularly suited the treatment of intestinal dysfunction in HIV patients.

Abstract: The present invention relates to a preventive and/or a therapeutic agent for inflammatory bowel diseases containing a fermentation product of a propionic acid bacterium as an active ingredient.

Abstract: A synergistic mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar using natural and synthetic ingredients. Numerous ratios may be formulated for aroma, color, flavor, flow (viscosity), taste and uniformity. Moreover, ingredients for sugar substitutes, natural preservatives, nano-dispersion, nano-emulsion, nano-encapsulation of ingredients and apparatus for personalized nutrition are also described herein.

Abstract: The present invention pertains to nutritional and pharmaceutical compositions for treating and preventing cyclooxygenase-2 mediated diseases and to a process for increasing the cyclooxygenase-2 inhibiting activity of a product. In addition thereto, the present invention relates to the use of one ore more milk protein fractions and/or one ore more milk protein preparations for inhibiting the activity of cyclooxygenase-2 (COX-2), in particular for the preparation of a medicament or a functional food for treating and preventing cyclooxygenase-2 mediated diseases.

Abstract: Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins.

Abstract: A method for the production of milk with increased melatonin content or a milk product made therefrom. The method comprises dividing the daily cycle of a female mammal into a daytime phase under a first light regime with a proportion of blue light and a night-time phase under a second light regime and milking the mammal at least once during the night-time phase in order to obtain milk with an increased melatonin content. For the second light regime there is used at least one light source which emits light in the wavelength range of 500 nm or above and substantially no light in the wavelength range below 500 nm.

Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerised immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerised immunoglobulins. The invention also relates to use of said compositions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.

Abstract: Use of glycomacropeptide to treat or prevent gout, use of one or more phospholipids and one or more gangliosides to treat or prevent gout, or use of glycomacropeptide and one or more phospholipids and one or more gangliosides to treat or prevent gout.

Abstract: The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder.

Abstract: This invention relates to products comprising antibiotics or probiotics and the use thereof for the treatment of gut motility disorders such as irritable bowel syndrome (IBS).

Abstract: The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

Abstract: The invention is a sexual hygienic preparation comprising extract prepared from the milk of at least one equid animal. The preparation may contain medically/therapeutically acceptable additive(s) in specified cases. The preparation is formulated preferably as a feminine cleansing gel, feminine cleansing shampoo, feminine cleansing soap, vaginal suppository, vaginal pill, vaginal cleansing liquid, concentrate, water-soluble solid vaginal cleansing preparation, effervescent tablet, granulate, powder, lyophylized Lactobacillus preparation, spermicide preparation; adsorbent material such as dry or wet wipe, sanitary pad, vaginal suppository, containing sexual hygienic preparation.

Abstract: Disclosed is: a visceral fat accumulation inhibitor or a food or drink for inhibiting the accumulation of a visceral fat, which composes a fat globule membrane component as an active ingredient; or a agent or food or drink for promoting the increase in the blood adiponection level and/or inhibiting the decrease in the blood adiponection level, which composes a fat globule membrane component as an active ingredient. A fat globule membrane component can inhibit the accumulation of a visceral fat, and/or can promote the increase in or inhibit the decrease in the blood adiponection level.

Abstract: The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and/or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

Abstract: The invention provides a method of treating a disorder characterised by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuro-protection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.

Abstract: The present application concerns plant extracts which have been fermented with kephir grains, methods of production of these extracts, a powder comprising these extracts and compositions comprising these extracts. Since these extracts have a high content of aglycone active principles, their biological activities are high and their applications are varied.

Abstract: Disclosed is a fermented milk product, which is useful for the promotion of good health. The fermented milk product is produced by fermenting a milk raw material with a combination of microorganisms consisting of (1) Lactobacillus kefiri and (2) at least one microorganism selected from the group consisting of Kazachstania turicensis, Kazachstania unispora and Kluyveromyces marxianus. Preferably, the fermented milk product is produced by fermenting the milk raw material with a combination of microorganisms consisting of at least Lactobacillus kefiri strain P-IF, Lactobacillus kefiri strain P-B1, Kazachstania turicensis strain P-Y3, Kazachstania unispora strain P-Y4 and Kluyveromyces marxianus strain P-Y5.

Abstract: A formulation for well-being in humans including: extracts from the herbal varieties, Polygonum multiflorum, Panax quinquefolium, Gingko biloba, and Equisetum arvense; beta sitosterol methyl sulfonyl methane; soy isoflavones; levo-arginine; inositol; niacin; pantothenic acid or salts thereof; alpha-tocopherol; biotin; pyridoxine hydrochloride zinc (or amino acid chelate thereof); and colostrum.

Abstract: Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins.

Abstract: The present invention provides cosmetic compositions and products that contain camel milk or components thereof, wherein the milk or components may be pre-treated by a physical or biochemical process. The invention further relates to a process for preparing cosmetic compositions containing camel milk or components thereof.

Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.

Abstract: The present disclosure includes disclosure of various embodiments of composition comprising a therapeutically-effective amount of a hyaluronate and a therapeutically-effective amount of colostrum. In at least one embodiment, the hyaluronate comprises sodium hyaluronate, and the colostrum comprises bovine colostrum. In an exemplary method of reducing osteoblastic activity within a warm-blooded vertebrate, the method comprises the step of administering a composition comprising a therapeutically-effective amount of a hyaluronate and a therapeutically-effective amount of colostrum to the warm-blooded vertebrate.

Abstract: A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

Abstract: A taste improving agent containing as an active ingredient a whey mineral satisfying all the criteria (a), (b), (c), (d), and (e) below: (a) an ash content in an solid portion of the whey mineral is 25 to 75% by mass; (b) a calcium content in a solid portion of the whey mineral is less than 2% by mass; (c) a calcium content in an ash portion of the whey mineral is less than 5% by mass; (d) a lactic acid content in a solid portion of the whey mineral is 1.0% by mass or more; and (e) a pH of an aqueous solution containing 0.1% by mass of a solid portion of the whey mineral is 6.0 to 7.5.

Abstract: A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

Abstract: The present invention is related to a method for the prevention and possibly the treatment of chronic diseases, preferably inflammatory associated chronic diseases that may affect an animal including a human, by the administration of a sufficient amount of a (functional) food or feed to the diet of this animal.

Abstract: Products as well as methods for reducing plaque in a domestic animal are provided. The product comprises retorted milk.

Abstract: Process for producing a beverage comprising a cocoa material having an enhanced level of polyphenols, the process comprising the steps of: (a) adding a base to an aqueous phase to adjust the pH to between about 6.5 and about 7.5, (b) mixing ingredients into the aqueous phase to give a dispersion, the ingredients including the cocoa material having an enhanced level of polyphenols, (c) performing a thermal treatment on the dispersion, comprising heating the dispersion to over about 85° C. for at least about 5 seconds, and (d) cooling the treated dispersion. A beverage obtainable by the process is also disclosed.

Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

Abstract: This application is in the field of sialic acid chemistry, metabolism, antigenicity, and the production of transgenic non-human mammals with altered sialic acid production. More particularly, this application relates to N-glycolylneuraminic acid (Neu5Gc) being an immunogen in humans, and the production of Neu5Gc-free mammalian products for laboratory and human use.